Literature DB >> 9503010

Characterization of the MADH2/Smad2 gene, a human Mad homolog responsible for the transforming growth factor-beta and activin signal transduction pathway.

S Takenoshita1, A Mogi, M Nagashima, K Yang, K Yagi, A Hanyu, Y Nagamachi, K Miyazono, K Hagiwara.   

Abstract

The transforming growth factor beta (TGF-beta) superfamily is a family of multifunctional cytokines that transduce signals via serine/threonine kinase receptors. Recent studies revealed that Mothers against dpp (Mad) in Drosophila and its homologs play important roles in the intracellular signal transduction of the serine/threonine kinase receptors. In mammals, one of the Mad homologs, MADH2 (also termed Smad2), was reported to be a mediator of TGF-beta and activin signaling and was found mutated in some of the colon and lung cancer cases. We describe here the genomic organization of the human MADH2 gene. The gene is composed of 12 exons; 2 exons 1, i.e., exon 1a and 1b, are used separately or in conjunction to form exon 1a-exon 1b-exon 2 alternatively spliced mRNA. The 2 exons 1 are closely located, and the MADH2 mRNAs are transcribed from two promoters in one CpG island. The promoter activity in the 5' upstream sequence was confirmed by the luciferase assay. The 3' end of the mRNA is heterogenous, and we found several polyadenylation signals. Northern blot analysis revealed high expression of the MADH2 mRNA, e.g., in skeletal muscle, heart, and placenta. RT-PCR assay using primers in exons 2 and 4 and direct nucleotide sequencing proved that exon 3 is spliced out in about 10% of MADH2 in human placenta. These data will be valuable for studying the MADH2 function in both normal cells and cancer cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9503010     DOI: 10.1006/geno.1997.5149

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  7 in total

1.  Postgastrulation Smad2-deficient embryos show defects in embryo turning and anterior morphogenesis.

Authors:  J Heyer; D Escalante-Alcalde; M Lia; E Boettinger; W Edelmann; C L Stewart; R Kucherlapati
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

2.  Mice exclusively expressing the short isoform of Smad2 develop normally and are viable and fertile.

Authors:  N Ray Dunn; Chad H Koonce; Dorian C Anderson; Ayesha Islam; Elizabeth K Bikoff; Elizabeth J Robertson
Journal:  Genes Dev       Date:  2005-01-01       Impact factor: 11.361

3.  Mutant p53 promotes tumor cell malignancy by both positive and negative regulation of the transforming growth factor β (TGF-β) pathway.

Authors:  Lei Ji; Jinjin Xu; Jian Liu; Ali Amjad; Kun Zhang; Qingwu Liu; Lei Zhou; Jianru Xiao; Xiaotao Li
Journal:  J Biol Chem       Date:  2015-03-12       Impact factor: 5.157

4.  Secretory leukocyte protease inhibitor reverses inhibition by CNS myelin, promotes regeneration in the optic nerve, and suppresses expression of the transforming growth factor-β signaling protein Smad2.

Authors:  Sari S Hannila; Mustafa M Siddiq; Jason B Carmel; Jianwei Hou; Nagarathnamma Chaudhry; Peter M J Bradley; Melissa Hilaire; Erica L Richman; Ronald P Hart; Marie T Filbin
Journal:  J Neurosci       Date:  2013-03-20       Impact factor: 6.167

5.  Epigenetic control of vascular smooth muscle cells in Marfan and non-Marfan thoracic aortic aneurysms.

Authors:  Delphine Gomez; Aurélie Coyet; Véronique Ollivier; Xavier Jeunemaitre; Guillaume Jondeau; Jean-Baptiste Michel; Roger Vranckx
Journal:  Cardiovasc Res       Date:  2010-09-09       Impact factor: 10.787

Review 6.  Modeling signal transduction from protein phosphorylation to gene expression.

Authors:  Chunhui Cai; Lujia Chen; Xia Jiang; Xinghua Lu
Journal:  Cancer Inform       Date:  2014-10-13

7.  Identification of crucial microRNAs and genes in hypoxia-induced human lung adenocarcinoma cells.

Authors:  Ying Geng; Lili Deng; Dongju Su; Jinling Xiao; Dongjie Ge; Yongxia Bao; Hui Jing
Journal:  Onco Targets Ther       Date:  2016-07-25       Impact factor: 4.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.